These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 32943072)

  • 41. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy.
    Chowdhury PS; Chamoto K; Honjo T
    J Intern Med; 2018 Feb; 283(2):110-120. PubMed ID: 29071761
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
    Li K; Tian H
    J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
    Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
    Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
    Ren D; Hua Y; Yu B; Ye X; He Z; Li C; Wang J; Mo Y; Wei X; Chen Y; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Zeng Z; Xiong W
    Mol Cancer; 2020 Jan; 19(1):19. PubMed ID: 32000802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
    Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
    J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differences in the risk of immune-related pneumonitis between PD-1 and PD-L1 inhibitors: a meta-analysis according to the new mirror-principle and PRISMA guidelines.
    Tian Y; Yin Z; Zhang C; Li Z; Wang Y; Zhang K; Chen F; Dang Q
    Cancer Immunol Immunother; 2024 Jul; 73(9):162. PubMed ID: 38953977
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
    Zhang D; Huang J; Zhang C; Guan Y; Guo Q
    Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):369-379. PubMed ID: 31196371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
    Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
    Front Immunol; 2019; 10():108. PubMed ID: 30778352
    [No Abstract]   [Full Text] [Related]  

  • 53. Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer.
    Chiang CL; Chen YW; Wu MH; Huang HC; Tsai CM; Chiu CH
    J Chin Med Assoc; 2016 May; 79(5):248-55. PubMed ID: 27036494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy.
    Li M; Gan L; Song A; Xue J; Lu Y
    Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):323-330. PubMed ID: 30826426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action.
    Zhang N; Tu J; Wang X; Chu Q
    Immunotherapy; 2019 Apr; 11(5):429-441. PubMed ID: 30698054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
    Song Y; Li Z; Xue W; Zhang M
    Immunotherapy; 2019 Apr; 11(6):515-529. PubMed ID: 30860441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
    Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
    Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations.
    Wang GX; Guo LQ; Gainor JF; Fintelmann FJ
    AJR Am J Roentgenol; 2017 Sep; 209(3):567-575. PubMed ID: 28657846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.